Lv21
128 积分 2022-04-14 加入
PSMA and FDG-PET as predictive and prognostic biomarkers in patients given [177Lu]Lu-PSMA-617 versus cabazitaxel for metastatic castration-resistant prostate cancer (TheraP): a biomarker analysis from a randomised, open-label, phase 2 trial
2小时前
已完结
Hormonal Agents in Localized and Advanced Prostate Cancer: Current Use and Future Perspectives
2个月前
已完结
Recent update on the development of EZH2 inhibitors and degraders for cancer therapy
3个月前
已完结
EZH1/EZH2 inhibition enhances adoptive T cell immunotherapy against multiple cancer models
3个月前
已完结
Reversing—or Rewiring—Lineage Plasticity? Lessons from EZH2 Loss in Prostate Cancer
3个月前
已完结
EZH2 Suppression Diversifies Prostate Cancer Lineage Variant Evolution and Lacks Efficacy in Inhibiting Disease Progression
4个月前
已完结
Combining PSMA-Targeted Radiopharmaceutical Therapy with Immunotherapy
5个月前
已完结
A Comprehensive Systematic Review and Meta-analysis of the Role of Prostate-specific Membrane Antigen Positron Emission Tomography for Prostate Cancer Diagnosis and Primary Staging before Definitive Treatment
8个月前
已完结
Targeting the tumour cell surface in advanced prostate cancer
8个月前
已完结
Novel Therapeutic Strategies for Metastatic Prostate Cancer Care
8个月前
已完结
皖公网安备34019202002308
